Skip to content
OpenCapital
Get started

Orthofix Medical Inc. OFIX EV / sales

EV / sales at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
Stryker logo
StrykerSYK
5.4×-1.3×
Globus Medical logo
Globus MedicalGMED
3.6×-0.2×
Alphatec Holdings logo
Alphatec HoldingsATEC
2.7×-0.3×
Enovis logo
EnovisENOV
1.2×-0.5×
OrthoPediatrics logo
OrthoPediatricsKIDS
1.6×-1.0×

Other financials

Income statement

See full
Revenue$196.7M+1.6%
Gross profit$139.5M+14.7%
Operating income-$14.4M+70.5%
Net income-$20.9M+60.6%
EPS (diluted)-$0.52+61.5%

Balance sheet

See full
Cash & equivalents$120.3M+108%
Total debt$237.5M+32.3%
Total equity$435.2M-5.0%
Total assets$886.6M+7.7%

Cash flow

See full
Operating cash flow-$17.6M+4.2%
CapEx$10.7M+58.3%
Free cash flow-$28.3M-12.5%

Valuation

See full
Market cap$376.33M-7.1%
Enterprise value$493.54M-6.3%
P/S0.5×0.0×

Profitability

See full
Gross margin70.7%+3.6pp
Operating margin-5.8%-2.1pp
Net margin-7.3%-2.7pp
FCF margin-9.3%-1.7pp

Returns & leverage

See full
Return on equity-13.4%-4.6pp
Debt / equity0.5×+0.2×
Current ratio2.9×+0.2×

Where this comes from

Calculated from Orthofix Medical Inc.’s reported figures.

enterprise value/total revenue=0.7×

Based on the most recent quarter.

The official record: Orthofix Medical Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Orthofix Medical Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Orthofix Medical Inc.'s EV / sales?
Orthofix Medical Inc. (OFIX) reported EV / sales of 0.7× in Q1 2026.
How has Orthofix Medical Inc.'s EV / sales changed year-over-year?
Orthofix Medical Inc.'s EV / sales decreased by 25.7% year-over-year, from 0.9× to 0.7×.
What is the long-term trend for Orthofix Medical Inc.'s EV / sales?
Over 5 years (2020 to 2025), Orthofix Medical Inc.'s EV / sales has grown at a -14.5% compound annual growth rate (CAGR), from 1.9× to 0.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.